Quest Diagnostics has launched MelaNodal Predict, an advanced predictive gene expression test for patients with melanoma, the company announced in a press release.
Lab-developed and validated by Quest Diagnostics in collaboration with SkylineDX, MelaNodal Predict examines a patient’s original skin cancer biopsy and applies an algorithm that combines patient age and tumor thickness with gene expression profiling technology to help providers identify which patients have a low or high risk of nodal metastasis.
«Melanoma test services are an important component of our broad portfolio of